Mapi is a development stage pharmaceutical company, engaged in the development of high-barrierto entry and high-added value life cycle management (“LCM”) products that target large marketsand generic drugs that include complex active pharmaceutical ingredients (“APIs”) and formulations. The GA Depot once every four weeks injection is the first in a series of depot long-acting injectionsin the company’s pipeline for the treatment of Multiple Sclerosis, an LCM of Copaxone, which requires daily or every second day injections. Mapi is built on strong chemical and pharmaceutical R&D capabilities, a deep understanding of the global market and of regulatory needs and its ability to foster local cooperation and enduring relationships in all of the countries in which it operates. Mapi is headquartered in Israel. It has R&D facilities in Israel and China. Mapi has a strong IP position, filing numerous patent applications for APIs and formulations.